AKUMS DRUGS AND PHARMA L Latest Share Price (AKUMS)
TODAY IN ONE LINE
AKUMS fell 2.0% on light volume, lagging Nifty's -0.5% move.
With a market cap of ₹10,718.53 Cr., it trades at a P/E of 36.75. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
AKUMS DRUGS AND PHARMA L flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●High Promoter HoldingPromoters hold 75.3% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.02x
- ●FII AccumulationFII holding increased by 2.59% QoQ
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 42.6% YoY
- ●Poor Capital ReturnsLow ROE of 7.7%
Latest AKUMS DRUGS AND PHARMA L News
What changed recently?
Recent events, corporate actions, and announcements.
AKUMS DRUGS AND PHARMA L valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for AKUMS DRUGS AND PHARMA L, framed against the sector median so the premium or discount is obvious at a glance.
AKUMS DRUGS AND PHARMA L trades at a P/E of 36.75× and P/B of 3.24×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
AKUMS DRUGS AND PHARMA L technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for AKUMS DRUGS AND PHARMA L — derived from the latest tape, not yesterday's close.
AKUMS DRUGS AND PHARMA L last traded at ₹680.2 with an intraday range of ₹675–₹695.25 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹680.20| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 732.47 | +52.27 | +7.68% |
| R3 | 712.22 | +32.02 | +4.71% |
| R2 | 703.73 | +23.53 | +3.46% |
| R1 | 691.97 | +11.77 | +1.73% |
| PIVOT | 683.48 | 3.28 | 0.48% |
| CURRENT | 680.20 | — | — |
| S1 | 671.72 | -8.48 | -1.25% |
| S2 | 663.23 | -16.97 | -2.49% |
| S3 | 651.47 | -28.73 | -4.22% |
| S4 | 631.22 | -48.98 | -7.20% |
AKUMS is trading Below CPR, indicating Bearishness
CPR is Average
Day's range: ₹680.1–₹695.25
Trading Below opening range, showing Bearishness
AKUMS DRUGS AND PHARMA L financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for AKUMS DRUGS AND PHARMA L — consolidated or standalone — with margins, YoY growth and key ratios inline.
AKUMS DRUGS AND PHARMA L reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹10,718.53 Cr. and reported EPS of ₹18.63.
| Metric | Mar 2026 | May 2026 |
|---|---|---|
| Revenue from Operations | 4,359 | 4,359 ▲ 0.0% |
| Sales Growth YoY %Derived | 5.85% | 5.85% |
| Other Income | 129 | 129 ▲ 0.0% |
| Total Income | 4,488 | 4,488 ▲ 0.0% |
| 2,514 | 2,514 ▲ 0.0% | |
| Gross ProfitDerived | 1,845 | 1,845 ▲ 0.0% |
| Gross Margin %Derived | 42.34% | 42.34% |
| 1,323 | 1,323 ▲ 0.0% | |
| EBITDA (Operating Profit)Derived | 522 | 522 ▲ 0.0% |
| OPM %Derived | 11.98% | 11.98% |
| 229 | 229 ▲ 0.0% | |
| Profit Before Tax (PBT) | 382 | 382 ▲ 0.0% |
| 126 | 126 ▲ 0.0% | |
| Effective Tax %Derived | 32.90% | 32.90% |
| Total Profit for Period | 256 | 256 ▲ 0.0% |
| Less: Non-controlling Interests | 1 | 1 ▲ 0.0% |
| Net Profit (Owner's PAT)Derived | 255 | 255 ▲ 0.0% |
| Net Profit Margin %Derived | 5.85% | 5.85% |
| PAT Growth YoY %Derived | -24.54% | -24.54% |
| Earnings Per Share (EPS ₹) | 16.21 | 16.21 ▲ 0.0% |
| Diluted Shares Outstanding (Cr) | 16 | 16 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | 1 | 1 ▲ 0.0% |
| Total Expenses (incl. D&A & Interest) | 4,106 | 4,106 ▲ 0.0% |
| Material Cost % of RevenueDerived | 52.73% | 52.73% |
| Employee Cost % of RevenueDerived | 17.29% | 17.29% |
| Other Cost % of RevenueDerived | 13.07% | 13.07% |
| Interest Coverage (x)Derived | 3.91x | 3.91x |
| Period | Mar 2025 | May 2025 | Mar 2026 | May 2026 | Trend |
|---|---|---|---|---|---|
| Revenue from Operations | 4,118 | 4,118 ▲ 0.0% | 4,359 ▲ 5.8% | 4,359 ▲ 0.0% | |
| Sales Growth YoY %Derived | — | — | 5.85% | 5.85% | |
| Other Income | 52 | 52 ▲ 0.0% | 129 ▲ 147.0% | 129 ▲ 0.0% | |
| Total Income | 4,170 | 4,170 ▲ 0.0% | 4,488 ▲ 7.6% | 4,488 ▲ 0.0% | |
2,433 | 2,433 ▲ 0.0% | 2,514 ▲ 3.3% | 2,514 ▲ 0.0% | ||
| Gross ProfitDerived | 1,685 | 1,685 ▲ 0.0% | 1,845 ▲ 9.5% | 1,845 ▲ 0.0% | |
| Gross Margin %Derived | 40.91% | 40.91% | 42.34% | 42.34% | |
1,220 | 1,220 ▲ 0.0% | 1,323 ▲ 8.5% | 1,323 ▲ 0.0% | ||
| EBITDA (Operating Profit)Derived | 464 | 464 ▲ 0.0% | 522 ▲ 12.4% | 522 ▲ 0.0% | |
| OPM %Derived | 11.28% | 11.28% | 11.98% | 11.98% | |
205 | 205 ▲ 0.0% | 229 ▲ 11.7% | 229 ▲ 0.0% | ||
| Profit Before Tax (PBT) | 345 | 345 ▲ 0.0% | 382 ▲ 10.7% | 382 ▲ 0.0% | |
1 | 1 ▲ 0.0% | 126 ▲ 8416.5% | 126 ▲ 0.0% | ||
| Effective Tax %Derived | 0.43% | 0.43% | 32.90% | 32.90% | |
| Total Profit for Period | 344 | 344 ▲ 0.0% | 256 ▼ 25.4% | 256 ▲ 0.0% | |
| Less: Non-controlling Interests | 6 | 6 ▲ 0.0% | 1 ▼ 78.4% | 1 ▲ 0.0% | |
| Net Profit (Owner's PAT)Derived | 338 | 338 ▲ 0.0% | 255 ▼ 24.5% | 255 ▲ 0.0% | |
| Net Profit Margin %Derived | 8.21% | 8.21% | 5.85% | 5.85% | |
| PAT Growth YoY %Derived | — | — | -24.54% | -24.54% | |
| Earnings Per Share (EPS ₹) | 21.49 | 21.49 ▲ 0.0% | 16.21 ▼ 24.6% | 16.21 ▲ 0.0% | |
| Diluted Shares Outstanding (Cr) | 16 | 16 ▲ 0.0% | 16 ▲ 0.0% | 16 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | -1 | -1 ▲ 0.0% | 1 ▲ 184.3% | 1 ▲ 0.0% | |
| Total Expenses (incl. D&A & Interest) | 3,825 | 3,825 ▲ 0.0% | 4,106 ▲ 7.3% | 4,106 ▲ 0.0% | |
| Material Cost % of RevenueDerived | 54.72% | 54.72% | 52.73% | 52.73% | |
| Employee Cost % of RevenueDerived | 17.38% | 17.38% | 17.29% | 17.29% | |
| Other Cost % of RevenueDerived | 12.25% | 12.25% | 13.07% | 13.07% | |
| Interest Coverage (x)Derived | 8.99x | 8.99x | 3.91x | 3.91x |
AKUMS DRUGS AND PHARMA L segment analysis : revenue and profit mix.
Disclosed business segments at AKUMS DRUGS AND PHARMA L with their share of revenue and profit, switchable between consolidated and standalone reporting.
AKUMS DRUGS AND PHARMA L discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for AKUMS DRUGS AND PHARMA L.
Our AI distills the core fundamental drivers supporting AKUMS DRUGS AND PHARMA L, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
AKUMS DRUGS AND PHARMA L's investment case rests on 0 positive markers and 1 flagged concerns drawn from the latest reported filings.
What you're getting.
No strengths or opportunities on record.
Key Risks.
SWOT generation temporarily unavailable due to model error. Bedrock invocation timeout
Flip Conditions.
Valuation risk. a P/E above 48 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 0.07%.
AKUMS DRUGS AND PHARMA L peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — AKUMS DRUGS AND PHARMA L is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
AKUMS DRUGS AND PHARMA L chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for AKUMS DRUGS AND PHARMA L — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
AKUMS DRUGS AND PHARMA L delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for AKUMS DRUGS AND PHARMA L over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in AKUMS DRUGS AND PHARMA L stood at 50.5% of traded volume, against a 20-day average of 51.2%.
AKUMS DRUGS AND PHARMA L announcements: results, concalls, ratings, M&A.
Filings AKUMS DRUGS AND PHARMA L sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
AKUMS DRUGS AND PHARMA L files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 160 documents below.
Action(s) taken or orders passed
Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Action(s) taken or orders passed
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018
Trading Window
Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider…
Analysts/Institutional Investor Meet/Con. Call Updates
Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Schedule of meet
Analysts/Institutional Investor Meet/Con. Call Updates
Akums Drugs and Pharmaceuticals Limited has informed the Exchange about Schedule of meet
Investor decks & rating reports.
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation
Investor Presentation
Investor Presentation
AKUMS DRUGS AND PHARMA L dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue AKUMS DRUGS AND PHARMA L has declared, sequenced by announce and record date.
AKUMS DRUGS AND PHARMA L corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About AKUMS DRUGS AND PHARMA L: business, sector, key facts.
What AKUMS DRUGS AND PHARMA L does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
AKUMS DRUGS AND PHARMA L operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: AKUMS, BSE: 544222.
Akums Drugs and Pharmaceuticals Limited is a pharmaceutical company based in Delhi, India, established in 2004. Their core business revolves around the manufacturing and sale of pharmaceutical products, encompassing both active pharmaceutical ingredients (APIs) and finished dosage forms. This dual approach allows them to participate in multiple stages of the pharmaceutical supply chain, offering a comprehensive service to both other pharmaceutical companies and directly to consumers.
A significant aspect of Akums' business model is its operation as a contract development and manufacturing organization (CDMO). This means they provide services to other pharmaceutical companies, manufacturing products according to their specifications. This contract manufacturing allows Akums to leverage their production capabilities to serve a broader market and diversify their revenue streams, reducing reliance on solely branded formulations.
Akums offers a wide range of dosage forms, catering to diverse needs within the pharmaceutical industry. Their product portfolio includes tablets, capsules (both hard and soft gelatin), liquid oral medications, sachets, vials, ampoules, form-fill-seal products, topical preparations, eye drops, dry powder injections, rotacaps, and gummies. This broad selection demonstrates their versatility and ability to handle various manufacturing processes and product formats. The diverse portfolio allows them to cater to a wider spectrum of clients and market demands.
In addition to its CDMO activities, Akums also engages in the sale of its own branded pharmaceutical formulations. This aspect of their business allows them to directly reach consumers with their products and develop their own brand recognition within the market. This dual strategy - combining CDMO services with branded product sales - allows for a more stable and diversified revenue stream and reduces reliance on any single business segment.
Akums' operations extend beyond India, indicating an established international presence. While the specific details of their international market share and distribution network aren't provided, the mention of international sales highlights their ambition to be a significant player in the global pharmaceutical landscape. Their success likely depends on factors such as maintaining high manufacturing standards, adhering to regulatory requirements in different markets, and developing a robust international distribution network.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- ALBERT DAVID (ALBERTDAVD) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about AKUMS DRUGS AND PHARMA L (AKUMS).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of AKUMS DRUGS AND PHARMA L (AKUMS)?
The current share price of AKUMS DRUGS AND PHARMA L (AKUMS) is ₹680.20. Today, the stock has declined by ₹13.85 (2%), trading in a range of ₹675.00 to ₹695.25. The stock opened at ₹680.10 with a trading volume of 3,02,529 shares.
02Is AKUMS DRUGS AND PHARMA L stock a good investment for long-term?
AKUMS DRUGS AND PHARMA L can be considered for long-term investment based on several factors. The company has a market capitalization of ₹10,718.53 Cr., P/E ratio of 36.75, ROE of 7.7%, and ROCE of 10.59%. The dividend yield stands at 0.14%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of AKUMS DRUGS AND PHARMA L stock?
The 52-week high price of AKUMS DRUGS AND PHARMA L (AKUMS) is ₹838.80, while the 52-week low is ₹409.30. Currently trading at ₹680.20, the stock is 66.19% above its 52-week low and 18.91% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy AKUMS DRUGS AND PHARMA L stock at the current price?
Whether to buy AKUMS DRUGS AND PHARMA L stock at ₹680.20 depends on multiple factors. The stock is currently trading with a P/E ratio of 36.75 and P/B ratio of 3.24. Today's performance shows a loss of 2%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of AKUMS DRUGS AND PHARMA L and when is the next dividend?
AKUMS DRUGS AND PHARMA L offers a dividend yield of 0.14%, which means for every ₹100 invested at the current price of ₹680.20, you can expect to receive approximately ₹0.14 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of AKUMS DRUGS AND PHARMA L?
AKUMS DRUGS AND PHARMA L's key financial metrics include: P/E Ratio: 36.75, P/B Ratio: 3.24, ROE: 7.7%, ROCE: 10.59%, Dividend Yield: 0.14%, EPS: ₹18.63, Book Value: ₹216.41, and Debt-to-Equity: 0.02. The company's market cap stands at ₹10,718.53 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is AKUMS DRUGS AND PHARMA L stock performing today in the market?
AKUMS DRUGS AND PHARMA L stock opened at ₹680.10 and is currently trading at ₹680.20, showing a decline of ₹13.85 (2%). The intraday high is ₹695.25 and low is ₹675.00. The trading volume stands at 3,02,529 shares, indicating moderate market participation today.
08What is the P/E ratio of AKUMS DRUGS AND PHARMA L and what does it indicate?
AKUMS DRUGS AND PHARMA L has a Price-to-Earnings (P/E) ratio of 36.75, which means investors are willing to pay 36.75 for every ₹1 of earnings. With an EPS of ₹18.63, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about AKUMS DRUGS AND PHARMA L (AKUMS) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.